

sirona
biochem

INVESTOR PRESENTATION

January 18, 2024

TSX-V: SBM

FSE: ZSB | OTC: SRBCF

FORWARD LOOKING STATEMENTS

Sirona Biochem cautions you that statements included in this presentation that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

TABLE OF CONTENTS

Investment Highlights	4
Share Information	5
Business Model Strategy	6
Product Pipeline	7
Worldwide IP Portfolio	10
Milestones	11
GlycoProteMim™	12
The Science	13
Studies and Results	14
Advantage	16

Sirona Laboratories™	18
Global Launch Plan	20
Projected Sales and Revenue	21
Anticipated Product Line	22
Facilities/M. Partners	23
Technology	24
Management	27
Contact Us	29
Sources	30

INVESTMENT HIGHLIGHTS

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Through its wholly-owned French subsidiary TFChem, the Company specializes in stabilizing carbohydrate molecules to improve efficacy and safety. Sirona Biochem's business model is to develop active ingredients for commercialization or for licensing out for upfront payments, milestones, and royalties.

- **Signed** global exclusive **licensing deal** with **Allergan Aesthetics**, an **AbbVie** [NYSE: ABBV] company, for **TFC-1067** and library of cosmetic compounds. [\[3\]](#)
- **Applied for an international trademark for TFC-1326, as GlycoProteMim™**, with the Instituto Nacional da Propriedade Industrial (INPI) and the United States Trademark and Patent Office
- **Ongoing royalty payments** on net sales generated by **AbbVie** product line based on licensed patented ingredients. Potential to cooperate on additional products with AbbVie.
- **Disruptive** proprietary carbohydrate-bonding platform based on 20 years of research and development.
- Strong worldwide IP portfolio, including North America, European Union, and Asia.
- **Cosmetics** - Developing disruptive solutions for anti-aging (\$12.5B USD) [\[5\]](#), cell preservation (\$7.5B USD) [\[7\]](#), and cellulite treatment (\$1.4B USD) [\[8\]](#).
- **Pharmaceutical** - Developing Anti-viral TBD compound for \$36B USD anti-viral market. [\[9\]](#)
- **State-of-the-art, multi-million dollar laboratory** in France with top scientific team, strong global manufacturing partner (Wuxi AppTec, China).

SHARE INFORMATION

TSX VENTURE
EXCHANGE

SBM

CAD\$0.12

OTCQB
EXCHANGE

SRBCF

USD\$0.088

FRANKFURT STOCK
EXCHANGE

ZSB

EUR€0.082

Shares owned by Insiders: 15%

Sirona Biochem is a publicly listed company traded on the
 TSX Venture (**TSX-V: SBM**), Börse Frankfurt (**FSE: ZSB**), and OTC (**OTC: SRBCF**)



FUNDAMENTAL DATA (CAD)	
TSX-V	SBM
Shares Outstanding	253,604,505
Shares Fully Diluted	275,429,505
Share Price (CAD)	\$0.12
Market Cap	\$30,432,541
Year High	\$0.215
Year Low	\$0.065

*January 18, 2024

BUSINESS MODEL & STRATEGY

Sirona Biochem's strategy is to
commercialize, license, or sell
patented compounds to leading
global companies in return for
up-front fees, milestone fees
and ongoing royalty payments.

PRODUCT PIPELINE

Cosmetic Products



 **sirona**
biochem

GlycoProteMim™
TFC-1326

TSX-V: SBM
FSE: ZSB | OTC: SRBCF

ADVANCING CHEMISTRY. ENHANCING HEALTH



 **sirona**
biochem

TFC-1067
An Innovative
Dark Spot Corrector
MAY 2022

TSX-V: SBM
FSE: ZSB | OTC: SRBCF

ADVANCING CHEMISTRY. ENHANCING HEALTH



 **sirona**
biochem

TBA
Cellulite Treatment

TSX-V: SBM
FSE: ZSB | OTC: SRBCF

ADVANCING CHEMISTRY. ENHANCING HEALTH

Pharmaceutical Products



 **sirona**
biochem

Anti-Viral

TSX-V: SBM
FSE: ZSB | OTC: SRBCF

ADVANCING CHEMISTRY. ENHANCING HEALTH

Sirona Biochem has invested extensively in developing its products to meet the need of patients and industry partners. The compounds created through our **proprietary platform** go through rigorous tests and regulatory scrutiny to verify their safety and efficacy.

COSMETIC PRODUCTS

Therapeutic Area	Compound	Status
Skincare - Dark spot corrector (Rx & OTC)	TFC-1067 & family of dark spot correctors	<ul style="list-style-type: none"> • Exclusive licensing deal with AbbVie for TFC-1067 signed [3]
Cell Preservation & Repair (incl keloid & scar therapy)	Glycoprotein Library	<ul style="list-style-type: none"> • In vitro testing for lead determination
Skincare - Anti-Aging/ Anti-wrinkle	GlycoProteMim™ (TFC-1326)	<ul style="list-style-type: none"> • Completed safety studies - awaiting dose approval and batch manufacturing for clinical trial [4] • In discussion for R&D partnership • Trademarking of GlycoProteMim™ name
Skincare - Cellulite Treatment	TBA	<ul style="list-style-type: none"> • Ongoing research & development

ESTIMATED MARKET SIZE

Skincare - Anti-Aging/Anti-wrinkle	\$12.5B USD [5] by 2024
Skincare - Dark spot corrector (Rx & OTC)	\$8B USD [6]
Cell Preservation & Repair (incl keloid & scar therapy)	\$7.5B USD [7]
Skincare - Cellulite Treatment	\$1.45B USD [8]

PHARMACEUTICAL PRODUCTS

Therapeutic Area	Compound	Status
Anti-viral	TBD (from library)	<ul style="list-style-type: none"> planning next studies

ESTIMATED MARKET SIZE

Anti-Viral

\$36.98B USD ^[9]

Sirona Biochem is continually discovering new compounds and molecules with the goal of advancing global health and skin care.

WORLDWIDE IP PORTFOLIO

Sirona Biochem has a **strong IP portfolio**, including a recently filed patent for its breakthrough **anti-aging compound GlycoProteMim™ (TFC-1326)**, managed by intellectual property law firm Cabinet Regimbeau [\[1\]](#)



REGIMBEAU
Creative IP

MILESTONES

Milestones achieved in the last 18 months:

- ✓ Completed an exclusive, global license with AbbVie for TFC-1067
- ✓ Completed the terms of manufacturing and supply of TFC-1067 for AbbVie
- ✓ Published research in the renowned Journal of Cosmetic Dermatology [\[13\]](#)
- ✓ Reached first product commercialization with TFC-1067 [\[2\]](#)
- ✓ Discovered potential anti-cellulite activity in compounds
- ✓ Successfully completed clinical trial for anti-aging GlycoProteMim™[\[14\]](#)
- ✓ Signed agreement with Pullan Consulting for negotiation and strategy on TFC-1067 [\[15\]](#)
- ✓ Developed a library of 20 novel antiviral compounds and completed initial screening for for library and completed initial screening for covid activity
- ✓ Completed a significant patent extension for the anti-aging compounds
- ✓ Initiated launch of Sirona Laboratories – for commercialization of GlycoProteMim™

Sirona is working intensively towards achieving the following milestones:

- Advance and patent the SGLT2 inhibitor in third therapy area
- Commercialize GlycoProteMim within newly formed subsidiary Sirona Laboratories
- Secure non-dilutive funding through grants
- File patents around novel compounds and therapy areas of interest
- Further R&D studies on library of Anti-Viral Compounds
- Continue to advance novel Cosmetic Ingredients in the areas of Cellulite and Wound-Care

**The milestones listed are not in chronological order. The achievement of milestones is mostly dependent on external partners and factors over which we have limited control. Accordingly, we will no longer provide a precise time estimate. We will immediately update shareholders on material items as they arise.*



GlycoProteMim™ TFC-1326

REDEFINING ANTI-AGING SCIENCE

GlycoProteMim™ (TFC-1326) represents a paradigm shift in the world of anti-aging skincare.

Our **cutting-edge active ingredient** is the culmination of **over US\$15 million** in research and development spanning 23 years.


Inspired by nature's own protective mechanisms, GlycoProteMim™ is poised to revolutionize the **US\$12.5 billion anti-aging and anti-wrinkle market.**^[5]

<https://www.glycoprotemim.com>


TFC-1326 (GlycoProteMim™): The Science

Novel Non-invasive Anti-Aging Anti-Wrinkle Technology

GlycoProteMim™ is based on the **naturally occurring glycoproteins** found in Antarctic fish, known to protect them against environmental stressors. **Dr. Géraldine Deliencourt-Godefroy developed and perfected GlycoProteMim™ (TFC-1326)** over a span of 23 years. Now, it is a clinically proven breakthrough compound, effective at reversing skin aging.



Aging reduces collagen and elastin production. Fibroblast activity declines resulting in **decreased elasticity and firmness**. The epidermal layer thins, **weakening the skin's protective barrier** and making it more susceptible to damage.




GlycoProteMim™ **heightens cellular response** to reactive oxygen species (ROS) and boosts SOD2. The compound also **enhances hyaluronic acid synthesis and increases fibroblast proliferation**, fortifying the collagen 1 network.

TFC-1326 (GlycoProteMim™): Studies and Results

Clinical Trial for GlycoProteMim™ in Paris

The clinical trial was designed to assess the compound's efficacy in reversing aging facial skin, including restoring lost volume (plumping) and reducing fine wrinkles. The formulation was a cream base with GlycoProteMim™ TFC-1326 at a concentration of 1%. The formulation included no other active ingredient. The cream was applied twice daily for 12 weeks.

The following results were achieved:



**Additional results are provided in our trial results news release and on our website.*

Results of using GlycoProteMim™ after 12 Weeks

Before

After



Skin is visibly more radiant and clear

Visible wrinkle reduction

Improved skin quality and density

Face reshaped due to tighter skin

Reduced inflammation

*Unretouched photos, taken in standard lighting. **Results may vary**

To best understand its numerous benefits and safety profile, **extensive testing on the cellular level** has also occurred in multiple research facilities. TFC-1326 has many properties **superior to the “gold standard”** retinoid based anti-aging products.

TFC-1326 (GlycoProteMim™): Advantage

GlycoProteMim™ stands out as a beacon of innovation and safety. Unlike traditional alternatives such as toxins, dermal fillers, and retinoids, GlycoProteMim™ offers a unique solution that is safe and effective in reversing skin aging.

GlycoProteMim™ TFC-1326

Safety for All Skin Types

GlycoProteMim™ is designed for all skin types. In stark contrast, alternatives such as retinoids, toxins, and dermal fillers, although considered safe, come with a list of potential adverse effects.

Anti-Aging Efficacy

Our patented compound not only boasts powerful anti-inflammatory effects but also reverses aging and repairs skin, offering a comprehensive and permanent solution. In contrast, alternatives only provide limited anti-aging benefits without reparative properties.

Natural Progression, Not Injection

GlycoProteMim™ is a topical application, avoiding the need for invasive injections. Unlike toxins and dermal fillers, which involve injection procedures, GlycoProteMim™ ensures a convenient and user-friendly experience without compromising on effectiveness.

Multifaceted Benefits:

From improving skin laxity and quality to providing UV protection and enhancing the skin barrier, GlycoProteMim™ outshines alternatives. Retinoids, while effective, come with challenges like skin irritation and a lengthy onset period, making GlycoProteMim™ a more versatile and user-friendly choice.

GlycoProteMim™ vs other anti-aging Compounds: Table

	GlycoProteMim (TFC - 1326)	Toxins	Dermal Fillers	Retinoids
	Unique patented Compound owned by Sirona Biochem	Botox®, Dysport®, Xeomin®, Jeuveau™	Juvéderm®, Multiple others	Tretinoin, Retinaldehyde, Retinol, Retinal, Retinyl acetate, Retinyl propionate, Retinyl palmitate
Application	Topical	Injection	Injection	Topical
Time to onset	8 weeks then progressive improvement	3-5 days	Immediate	Up to 6 months
For Sensitive Skin	Safe	Safe	Safe	Avoid Use
Adverse Effects	None to date	Yes, long list of side effects	Yes, long list of side effects	Yes, irritant reaction in 10%
Anti-inflammatory Effect	Powerful	None	None	Mixed Effect
Anti-Aging Effect	Reverses Aging / Repairs	None	None	Forces skin reproduction
Antioxidant	Yes	No	No	Yes
Anti-Wrinkle	Yes	Yes	Yes	Yes, with Prescription Strength
Improve Skin Laxity	Yes	No	Yes	No
Improve Skin Quality	Yes	No	No	Yes, but limited
Face Shape Remodeling	Yes	No	Yes	No
UV Protection	Yes	No	No	No, avoid UV light
Improve Skin Barrier	Yes	No	No	No, damages skin barrier
Cruelty-Free	Yes	No	No	No

GlycoProteMim™ presents a groundbreaking alternative to the current “gold standard” retinoid-based treatments. Unlike retinoids, which compromise the skin’s barrier and lead to side effects such as flaking, peeling, redness, irritation, and increased sensitivity, GlycoProteMim™ enhances the skin barrier and repairs the skin from the inside out without any adverse effects.

GlycoProteMim™ is not just a product but a paradigm shift in anti-aging skincare.



sirona

laboratories™

Introducing **Sirona Laboratories™**, our new wholly-owned cosmetics subsidiary. Established with a vision to maximize the commercial potential of our breakthrough anti-aging skincare ingredient, **GlycoProteMim™**. Sirona Laboratories represents a strategic leap into the aesthetics market and the future of skincare.

In our pursuit to redefine the anti-aging skincare market, we chose to create Sirona Laboratories™ as a distinct entity. This decision was prompted by GlycoProteMim™'s **amazing clinical trial results** and our commitment to setting a new benchmark in the industry.

powered by

GlycoProteMim™

TFC-1326




Changing the Game

Through **Sirona Laboratories™**, we are aiming to achieve several ambitious goals. Our primary objectives include establishing GlycoProteMim™ as the **new “Gold Standard” in anti-aging skincare** ingredients, while also setting new standards in effectiveness and safety.

To realize these goals, we’re strategically collaborating with industry experts to harness our clinically proven science. These efforts are not just about commercial success; they are about creating sustainable value for our shareholders and the entire skincare industry.

GLOBAL LAUNCH PLAN



PHASES OF DISTRIBUTION

Phase 1 - Q1 2025

- USA
- Canada

Phase 2 - Q4 2025


- Europe
- Gulf States
- Australia & New Zealand

Phase 3

- China
- South Korea
- Japan

PROJECTED SALES AND REVENUE

Projected Sales with Expected Return Customers



Assuming 70% of customers continue to buy product over the next months
 Assuming consistent 25% sales growth per month

Total Prejected Units Sold for 2025 - 84,000 units
 Total Revenue - **\$21 million**
 Total Margin - **\$18.9 million**

ANTICIPATED PRODUCT LINE



Anti-Aging Series

- Anti-Aging Serum Ampoules
- (0.5%) Anti-Aging Cream
- (0.2%) Mild Anti-Aging Cream

Therapeutic Series

- Anti-Cellulite Cream
- Hand Cream

FACILITIES/MANUFACTURING PARTNER

Sirona Biochem Laboratory

TFChem Laboratory, France

The 502-square-meter laboratory is located in Val de Reuil, France. This state-of-the-art facility is located in France's Cosmetic Valley, where the world's leading cosmetic companies conduct their research and development.

The award-winning team working at the facility specializes in developing fluorinated building blocks, which addresses the limitations usually associated with the application of carbohydrate-based molecules as active ingredients.

www.sironabiochem.com

Manufacturing Partner - TFC-1067

WuXi AppTec, China

WuXi AppTec provides a broad R&D and manufacturing services portfolio that enables the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients.

The company has research, development, and manufacturing facilities in China, South Korea, the U.S., Germany, the UK, Switzerland, and Israel.

www.wuxiapptec.com

Anti-aging: GlycoProteMim™ Laboratory

DIVA Laboratory, France

We're currently working with DIVA on anti-aging.

www.diva-expertise.com



TECHNOLOGY

Our world-class team is comprised of **award-winning scientists** who have worked for Fortune 500 companies such as **Sanofi, GSK** and **Bayer**.



Carbohydrate compounds have immense commercial potential.

- They are involved in many of our body's biological processes and are also used for development of active ingredients in pharmaceuticals and cosmetics

Examples of successful carbohydrate-based drugs are:

- Anti-viral medications such as **Tamiflu**, used for the treatment of Influenza A
 - Tamiflu: sales passed \$931 Million USD during swine flu epidemic (2019) [\[24\]](#)
- Blood thinners, such as: **Arixtra** and **Lovenox**, for the treatment of blood clots
 - Lovenox: sales of \$1.46 Billion USD (2018) [\[25\]](#)

Geraldine Deliencourt-Godefroy, PhD

Founder, TFChem
Chief Scientific Officer

Our Technology has received more than **\$8M CAD** in grants from the French Government, including new financing to develop its advance chemistry process.

The challenges with carbohydrates are:

- Carbohydrates have complex syntheses requiring expert chemists
- Carbohydrates are unstable, causing lower efficacy or toxic by-products
- Carbohydrates have poor pharmacological properties


Sirona Biochem's
 proprietary chemistry
increases the potential and
reduces the drawbacks
 of carbohydrate molecules

- Sirona's Fluorination Chemistry Technology is **the solution** to **unstable carbohydrate molecules**.

- The chemistry strengthens the bonds of a carbohydrate molecule by strategically placing fluorine atoms.

Carbohydrate molecules
 are unstable by nature

Sirona's technology
 stabilizes carbohydrate
 molecule



MANAGEMENT



Howard J. Verrico, MD

Founder, Sirona Biochem
CEO and Chairman of the Board

Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets. He has acted as a venture capitalist for over 30 years, funding numerous start-ups and early-stage companies both in the private and public marketplace. He is the original founder of Sirona Biochem building the company by investing his personal funds starting in 2006. He has accumulated his large share position through personal share purchases. He currently is solely focused on the success and growth of SIRONA Biochem as it enters a stage of rapid growth.



Geraldine Deliencourt-Godefroy, PhD

Founder, TFChem
Chief Scientific Officer

Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of French-based biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology for stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Masters in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, French Ministry of Research Award and the French Senate Award.



Christopher Hopton, CPA, CGA

Chief Financial Officer

Christopher Hopton, Sirona Biochem's Chief Financial Officer, brings 28 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hopton has worked with several public and privately-held companies. Most recently, Mr. Hopton was the Chief Financial Officer of Central Resources Corp., a junior mineral exploration company. Formerly, he held the position of Division Controller at Canadian Airlines where he was responsible for an annual operating budget of \$200M. Mr. Hopton was also involved in the restructuring of 360 Networks, a network communications company, which led to a buyout by Bell Canada. Mr. Hopton earned his Bachelor of Business Administration from Simon Fraser University in British Columbia, Canada and received his professional designation as a Certified General Accountant.

CONTACT US

Sirona Biochem: Corporate Office
Parent Company - founded 2009



Sirona Biochem Corp.
c/o WeWork
595 Burrard Street,
Vancouver, BC
V7X 1L4

PHONE: +1.604.641.4466
EMAIL: info@sironabiochem.com
WEBSITE: www.sironabiochem.com

TFChem: Laboratory
Wholly Owned Subsidiary - acquired in 2011



TFChem
Voie de l'innovation
Pharma Parc II
27100 Val de Reuil
France

PHONE: +33(0)2.32.09.01.16
FAX: +33(0)2.32.25.07.64
EMAIL: contact@tfchemistry.com

SOURCES

1. <https://onlinelibrary.wiley.com/doi/10.1111/jocd.13771>
2. <https://www.rodanandfields.cotm/en-us/shop/targeted-dark-spot-corrector/p/RVST015>
3. <https://www.globenewswire.com/news-release/2022/06/13/2461193/0/en/Sirona-Biochem-Announces-Exclusive-Global-Licensing-Agreement-with-Allergan-Aesthetics.html>
4. <https://www.biospace.com/article/releases/sirona-biochem-reports-positive-results-in-safety-study-for-anti-aging-compound-tfc-1326/>
5. <https://www.factmr.com/report/4337/anti-aging-and-anti-wrinkle-products-market>
6. <https://www.grandviewresearch.com/industry-analysis/skin-lightening-products-market>
7. <https://www.globenewswire.com/news-release/2021/09/22/2301486/0/en/Cell-and-Tissue-Preservation-Market-to-Surpass-US-8-5-Billion-by-2028-CAGR-11-5-Says-Acumen-Expert.html>
8. <https://www.grandviewresearch.com/industry-analysis/cellulite-treatment-market>
9. <https://www.reportsanddata.com/press-release/global-antiviral-drugs-market>
10. <https://www.mordorintelligence.com/industry-reports/sglt-2-market>
11. <https://www.sironabiochem.com/sirona-biochem-adds-french-patenting-top-gun-lawyer-to-its-scientific-advisory-board/>
12. <https://www.newswire.ca/news-releases/sirona-biochem-reports-excellent-results-in-new-clinical-study-on-tfc-1067-881933919.html>
13. <https://markets.businessinsider.com/news/stocks/sirona-biochem-announces-acceptance-of-clinical-study-for-tfc-1067-in-the-journal-of-cosmetic-dermatology-1029718558>
14. <https://www.globenewswire.com/news-release/2014/09/22/1343131/0/en/Sirona-Biochem-Launches-Anti-Aging-Preclinical-Studies.html>
15. <https://www.newswire.ca/news-releases/sirona-biochem-announces-engagement-of-pullan-consulting-to-close-optimal-deal-for-tfc-1067-803127057.html>
16. <https://www.bloomberg.com/press-releases/2020-03-31/-r-e-p-e-a-t-sirona-biochem-initiates-covid-19-and-infectious-diseases-development-program>
17. <https://www.gminsights.com/industry-analysis/animal-healthcare-market>
18. <https://vetsource.com/news/pet-diabetes-facts/>
19. <https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2021-financial-results/>
20. <https://www.boehringer-ingelheim.com/media-overview/press-releases/boehringer-ingelheim-good-2021-business-performance>
21. <https://investor.zoetis.com/news/news-details/2022/Zoetis-Reports-Fourth-Quarter-and-Full-Year-2021-Results/default.aspx>
22. <https://covetrus.com/covetrus-announces-financial-results-for-fourth-quarter-and-full-year-of-2021/>
23. <https://investor.elanco.com/press-releases/press-releases-details/2022/Elanco-Animal-Health-Reports-Fourth-Quarter-and-Full-Year-2021-Results/default.aspx>
24. <https://www.nytimes.com/2009/07/24/business/24roche.html>
25. <https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/press-releases/Q42018results.pdf>



sirona
biochem

TSX-V: SBM
FSE: ZSB | OTC: SRBCF